🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT07714941
Starting soon Observational

EUS-Guided ATI and SWE in Individuals With Normal FibroScan

NCT07714941 · tracked via the Priya Life Science India tracker
Sponsor
Asian Institute of Gastroenterology, India
Phase
Observational
Started
2026-08-20
Last updated
2026-07-20

Condition(s) studied

Non-hepatobiliary Indications

Investigational drug(s) / intervention(s)

Endoscopic Ultrasound (EUS)EUS-guided Attenuation Imaging (ATI)EUS-Guided Shear Wave Elastography (SWE)FibroScan

Endoscopic Ultrasound (EUS): A clinically indicated diagnostic endoscopic ultrasound will be performed according to standard institutional practice. During the examination, the liver will be visualized from the stomach and duodenum to allow quantitative liver assessment.

EUS-guided Attenuation Imaging (ATI): Attenuation Imaging (ATI) will be performed during the diagnostic EUS to quantitatively assess hepatic steatosis. Five valid ATI measurements will be obtained from both the right and left hepatic lobes under direct EUS visualization. Measurements meeting predefined quality criteria will be used for analysis.

EUS-Guided Shear Wave Elastography (SWE): Shear Wave Elastography (SWE) will be performed during the diagnostic EUS to assess liver stiffness. Ten valid measurements will be obtained from both the right and left hepatic lobes. Shear wave velocity (m/s) and tissue elasticity (kPa) will be recorded, and only measurements meeting predefined quality criteria will be included in the analysis.

FibroScan: Participants will undergo same-day FibroScan examination before EUS to confirm normal liver stiffness and steatosis. Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) will be recorded, with at least 10 valid measurements and acceptable quality metrics required for study eligibility.

Study summary

The goal of this observational study is to establish preliminary reference values for Endoscopic Ultrasound (EUS)-guided Attenuation Imaging (ATI) and Shear Wave Elastography (SWE) in adults undergoing diagnostic EUS for non-hepatobiliary indications who have normal FibroScan findings. The main questions it aims to answer are:

What are the preliminary normal reference values for EUS-guided ATI in the right and left hepatic lobes? What are the preliminary normal reference values for EUS-guided SWE elasticity (kPa) and velocity (m/s) in the right and left hepatic lobes?

Participants will:

Undergo same-day FibroScan assessment to confirm normal liver stiffness and steatosis parameters.

Undergo EUS-guided ATI and SWE measurements of both the right and left hepatic lobes during their clinically indicated diagnostic EUS examination.

Have demographic, clinical, and laboratory information recorded for analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years or older. * Undergoing clinically indicated diagnostic endoscopic ultrasound (EUS). * Same-day FibroScan examination available. * Controlled Attenuation Parameter (CAP) \<238 dB/m. * Liver Stiffness Measurement (LSM) \<7.5 kPa. * At least 10 valid FibroScan measurements. * FibroScan interquartile range (IQR)/median ≤30%. * Able and willing to provide written informed consent. Exclusion Criteria: * Known chronic liver disease. * Hepatitis B or Hepatitis C infection. * Significant alcohol consumption. * Decompensated cirrhosis. * Portal vein thrombosis. * Ascites. * Focal liver lesion. * Previous liver surgery. * Pregnancy. * Inadequate FibroScan examination. * Poor-quality EUS-guided Attenuation Imaging (ATI) or Shear Wave Elastography (SWE) acquisition. * Incomplete study data or withdrawal of informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
AIG Hospitals Hyderabad Telangana

More Asian Institute of Gastroenterology, India trials in India

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07714941 on ClinicalTrials.gov ↗ ← All trials in India